
GSK and CureVac in mRNA technology collaboration
27 July 2020 Image: CDC GlaxoSmithKline and CureVac are collaborating for the research, development, manufacturing and commercialisation of up to five mRNA-based vaccines and monoclonal antibodies (mAbs) targeting infectious disease pathogens. The collaboration complements GSK’s existing mRNA capabilities with CureVac’s integrated mRNA platform. mRNA (messenger RNA) technology is… Read More















